Form 8-K

8-K — Lantern Pharma Inc.

Accession: 0001493152-26-037979

Filed: 2026-08-14

Period: 2026-08-14

CIK: 0001763950

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

EX-99.2 (ex99-2.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-2_001.jpg)

GRAPHIC (ex99-2_002.jpg)

GRAPHIC (ex99-2_003.jpg)

GRAPHIC (ex99-2_004.jpg)

GRAPHIC (ex99-2_005.jpg)

GRAPHIC (ex99-2_006.jpg)

GRAPHIC (ex99-2_007.jpg)

GRAPHIC (ex99-2_008.jpg)

GRAPHIC (ex99-2_009.jpg)

GRAPHIC (ex99-2_010.jpg)

GRAPHIC (ex99-2_011.jpg)

GRAPHIC (ex99-2_012.jpg)

GRAPHIC (ex99-2_013.jpg)

GRAPHIC (ex99-2_014.jpg)

GRAPHIC (ex99-2_015.jpg)

GRAPHIC (ex99-2_016.jpg)

GRAPHIC (ex99-2_017.jpg)

GRAPHIC (ex99-2_018.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001763950

2026-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 14, 2026

Lantern

Pharma Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

1920

McKinney Avenue, 7th Floor

Dallas,

Texas

75201

(Address

of Principal Executive Offices)

(Zip

Code)

(972)

277-1136

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act: Common Stock

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, $0.0001 par value

LTRN

The

Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

August 14, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the

second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is

incorporated herein by reference.

The

information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless

of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item

7.01 Regulation FD Disclosure.

August 14, 2026, the Company will utilize a presentation to assist with the Company’s discussions during a conference call and

live webinar hosted by the Company to discuss financial and operating results for the second quarter ended June 30, 2026. A copy of the

presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information in this Item 7.01, including Exhibit 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless

of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Exhibit

Description

99.1

Press Release dated August 14, 2026 announcing financial results for second quarter ended June 30, 2026.

99.2

Presentation relating to August 14, 2026 conference call and live webinar to discuss financial and operating results for quarter ended June 30, 2026.

104

Cover

Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Lantern

Pharma Inc.,

Delaware Corporation

Dated:

August 14, 2026

By:

/s/

David R. Margrave

David

R. Margrave, Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Lantern

Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Open

Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon

21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial; LP-184 Development Positioned

to Advance in Multiple Indications including Triple Negative Breast Cancer and Pediatric Brain Cancers

● Open

Medicine AI (OMAI) established as a separate company with board-approved commercial licensing

agreements executed, operating the multi-agentic AI co-scientist platform previously launched

as withZeta.ai. OMAI is currently wholly owned by Lantern and intends to raise capital at

the OMAI level. A dedicated OMAI informational call is planned for mid-September 2026 to

detail the market opportunity, platform roadmap, and commercial model.

● LP-300

– HARMONIC™ benefit deepens with treatment duration in emerging dataset:

Median progression-free survival of 8.9 months in EGFR exon 21 L858R patients who completed

six cycles of LP-300 (n=9), compared with 8.4 months across the overall L858R cohort (n=16),

and a hazard ratio of 0.37 (95% CI 0.15–0.89) favoring the L858R subgroup. A 77% clinical

benefit rate and tumor reduction in more than 70% of evaluable patients, with durable responses

beyond two years — and no clinically meaningful toxicity added beyond chemotherapy.

● Phase

2 protocol amendment FDA-reviewed with no objections to key proposed amendments: enrollment

will now be concentrated on EGFR exon 21 L858R patients with a single-arm design, and maximum

LP-300 treatment extended from six to eight cycles. Enrollment will continue at sites in

the United States and Taiwan.

● EMA

clearance in bladder cancer for LP-184 (zirdafulven): an investigator-initiated Phase

1b/2 trial of zirdafulven at Rigshospitalet in Denmark, among the first studies to prospectively

select patients using a dual biomarker strategy — PTGR1 overexpression combined with

tumor DNA-damage repair deficiency.

● FDA

cleared triple-negative breast cancer (TNBC) clinical trial advancing toward initiation:

a planned Phase 1b/2 trial of LP-184 monotherapy in relapsed/refractory advanced or metastatic

TNBC with homologous recombination deficiency.

● USPTO

Notice of Allowance received for claims covering a three-gene expression signature used

to select patients for treatment with LP-184 across four solid tumor indications.

● Financial

Position: Cash, cash equivalents, and marketable securities of approximately $7.4 million

as of June 30, 2026. Funding received in the second quarter consisted of approximately $4.4

million in gross proceeds from the registered direct offering that closed on May 14, 2026.

Second quarter loss from operations decreased approximately 25% year over year, to approximately

$3.5 million for Q2 2026.

● Conference

call and webcast scheduled for Friday, August 14, 2026 at 9:00 a.m. ET.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

DALLAS–(BUSINESS

WIRE)– Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary

RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology

drug discovery and development, today announced operational highlights and financial results for the second quarter ended June 30, 2026,

and provided an update on its portfolio of AI-driven drug candidates and AI platforms.

The

second quarter of 2026 marked continued execution of Lantern’s strategy to translate its AI platform into differentiated clinical,

regulatory, intellectual property, and commercial milestones. Emerging data from the HARMONIC™ trial indicated that LP-300’s

progression-free survival benefit deepens with longer treatment duration in patients with EGFR exon 21 L858R-mutations, while the FDA

reviewed key protocol amendments without objection. The European Medicines Agency (EMA) cleared an investigator-initiated Phase 1b/2

trial of LP-184 (zirdafulven) for biomarker-selected, advanced bladder cancer patients, and the U.S. Patent and Trademark Office issued

a Notice of Allowance covering a three-gene patient-selection signature for LP-184. In August, Lantern established Open Medicine AI as

a separate company and entered into board-approved commercial licensing agreements. Reflecting ongoing operating discipline, loss from

operations declined approximately 25% year over year for the quarter.

“The

emerging HARMONIC™ data point to a clear observation: L858R patients who stay on LP-300

longer do better,” said Panna Sharma, President and Chief Executive Officer of Lantern

Pharma. “A signal that strengthens with time should shape trial design, and that

is exactly what our amended protocol does — concentrate enrollment where the benefit

is deepest and extend treatment from six cycles to eight. The FDA reviewed those amendments

without objection.

“The

quarter also showed what our AI-enabled model produces: a Notice of Allowance on the patient-selection signature for LP-184, European

clearance to administer that drug in a dual-biomarker-selected bladder cancer trial, and Open Medicine AI established as a separate company.

We have advanced new programs from AI-derived insights to first-in-human clinical trials in roughly two to three years at approximately

$2 to $3 million each. The industry norm to reach that same point is five to ten years and $25 to $100 million. That difference is not

a marketing claim; it is our operating model.”

With

the establishment of Open Medicine AI, Lantern has two value-creation engines:

1. A

clinical-stage, precision oncology drug development business advancing biomarker-guided

therapies across solid tumors, blood cancers, and pediatric brain cancers; and

2. An

AI platform business addressing the opportunity in AI-enabled drug discovery, the market

for which is projected to exceed $10 billion by 2030, with oncology as its largest therapeutic

segment.

Open

Medicine AI: Establishment as a Separate Company

August 2026, Lantern announced the formal creation of Open Medicine AI (OMAI) and the execution of commercial licensing agreements between

OMAI and Lantern Pharma. The agreements, approved by the Lantern Pharma Board of Directors, were contemplated in the framework of the

Company’s May 2026 registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist

platform previously launched as withZeta.ai. Under the agreements, OMAI licenses Lantern’s related models, data, algorithms, and

other assets and personnel.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

“Open

Medicine AI is not a research project with a logo on it. It has board approval, executed

licenses, a platform in production, paying subscription tiers, and two engineering centers.

We believe that this is a great foundation from which to attract investors who can value

AI and a technology-centric disruptive business separate from our portfolio of cancer drug-candidates,”

said Mr. Sharma, who is the Founder of Open Medicine AI and continues as President and Chief

Executive Officer of Lantern Pharma. “Separating OMAI is intended to let each business

be funded by the investors who understand it and valued on the metrics that apply to it.”

OMAI

is currently 100% owned by Lantern Pharma. OMAI intends to obtain additional funding in exchange for equity in OMAI, and the longer-term

objective is for OMAI to become a newly listed company on a national stock exchange or market, with Lantern expecting to remain one of

OMAI’s largest shareholders. As OMAI receives outside funding, additional operational and success incentives are expected to be

put in place for the Open Medicine AI team.

Today

OMAI is a wholly-owned subsidiary, and Lantern retains the ability to apply the platform across its clinical pipeline and preclinical

assets, including LP-184, LP-284, and LP-300, and the separation does not alter the priority or expected timing of those programs, which

remain the Company’s principal clinical value drivers.

OMAI

will operate as a commercial software business through tiered subscriptions based on functionality and tool access, alongside enterprise

agreements for organizations requiring broader deployment and integration with internal data and workflows. Target customers include

biopharmaceutical and biotechnology R&D organizations, academic medical centers, life sciences investors, and disease foundations.

The platform comprises coordinated specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers

and translational science, and clinical oncology. Development is anchored by AI Centers of Excellence in Dallas, Texas and Bengaluru,

India, the latter established in the first quarter of 2026. In July 2026, the Company launched ZetaOmics™, the computational-biology

module of the platform — an autonomous “Computational Biologist” agent that designs an analysis, executes it independently

on real biological data, defends its methodological choices, and returns publication-quality results with a queryable, exportable audit

trail suited to regulated research.

Management

will host a dedicated informational call and webcast in mid-September 2026 to discuss the Open-Medicine AI market opportunity, platform

roadmap, and commercial model in greater detail. Details will be announced separately.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

Clinical

Pipeline Developments

Lantern’s

AI-driven clinical pipeline encompasses multiple drug candidates across solid tumors, blood cancers, and pediatric oncology, with a combined

estimated annual market potential exceeding $15 billion. The portfolio includes a Phase 2 clinical program (LP-300) in NSCLC focused

on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; Phase 1b/2 trial (LP-184) in precision, biomarker-defined advanced

bladder cancer; and an ongoing Phase 1a program in hematologic malignancies and soft tissue sarcomas (LP-284). Additionally, through

wholly-owned subsidiary Starlight Therapeutics, the Company has a planned Phase 1 pediatric CNS cancer trial and a planned Phase 1b trial

in adult relapsed glioblastoma (GBM) in combination with spironolactone, both with STAR-001 (LP-184). Each program has been guided by

the RADR® platform’s AI-driven insights and capabilities which are aimed at compressing the cost and timeline of

cancer drug development.

LP-300

HARMONIC™ Trial: Progression-Free Survival Benefit Deepens With Treatment Duration

June 2026, Lantern reported emerging data from the ongoing Phase 2 HARMONIC™ trial (NCT05456256) of LP-300 in combination with

carboplatin and pemetrexed as of the May 11, 2026 data cutoff. The data revealed a dose-duration relationship in which the progression-free

survival benefit of LP-300 deepens with treatment duration, most pronounced in patients with the EGFR exon 21 L858R mutation.

● Progression-Free

Survival: Median progression-free survival reached 8.9 months among L858R patients who

completed six cycles of LP-300 (n=9, of whom three had not progressed at the time of analysis),

compared with 8.4 months across the overall L858R cohort (n=16). The L858R subgroup corresponded

to a hazard ratio of 0.37 (95% CI 0.15–0.89).

● Depth

and Durability of Response: More than 70% of evaluable L858R patients experienced a reduction

in target-lesion size, including a complete response and multiple partial responses among

the deepest responders, with certain responses sustained beyond two years and a clinical

benefit rate of 77%.

● Dose-Duration

Relationship: Comparable safety profiles were observed across patients receiving four

or six cycles of LP-300, with no evidence of increased adverse events with longer treatment

duration. This trend is consistent with LP-300’s kinase inhibitory mechanism of action

and provides supporting scientific rationale for extending the maximum number of treatment

cycles from six to eight.

● Safety

and Tolerability: No clinically meaningful toxicity was observed beyond that of carboplatin

and pemetrexed alone. Lantern believes this profile compares favorably with amivantamab plus

chemotherapy on a cross-trial basis and supports the extended treatment duration.

Preliminary

multivariable Cox regression analyses incorporating race, gender, and TP53 mutation status confirmed L858R as an independent predictor

of progression-free survival benefit. These data are exploratory and based on small patient cohorts. Following a successful outcome from

its May 2026 Type C meeting request, at which the FDA raised no objections to key proposed amendments, the Company has implemented protocol

changes that: (i) focus future enrollment on patients with the EGFR exon 21 L858R mutation, a subtype demonstrating lower sensitivity

and inferior treatment outcomes with osimertinib-based therapy; (ii) increase the maximum number of LP-300 treatment cycles from six

to eight; and (iii) discontinue enrollment into the control arm while migrating to a single-arm study design.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

The

HARMONIC™ trial will continue to enroll in the United States and in Taiwan, where more than 50% of lung cancer cases occur in never-smokers;

targeted enrollment in Japan was completed in July 2025 across five clinical sites including the National Cancer Center Tokyo. The Company

furnished its data presentation as an exhibit to a Current Report on Form 8-K and used the dataset in partnering and clinical discussions

at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including potential global and regional licensing and co-development

opportunities. Never-smoker NSCLC is increasingly recognized as a distinct disease entity with unique clinical and genomic characteristics,

representing a global market opportunity estimated at over $4 billion annually, with no therapies specifically approved for these patients.

LP-184

(zirdafulven): EMA Clearance for Biomarker-Selected Bladder Cancer Trial

July 2026, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 clinical trial of LP-184 (zirdafulven) in advanced,

recurrent bladder cancer. The study will be conducted at Rigshospitalet in Copenhagen, Denmark’s national referral center for urologic

cancers, with Professor Kristoffer Staal Rohrberg, MD, PhD, serving as Sponsor and Principal Investigator and Professor Helle

Pappot, MD, DMSc, serving as Coordinating Investigator.

The

open-label study is designed to enroll up to approximately 39 patients with advanced or metastatic urothelial carcinoma who have progressed

on or are ineligible for current standard-of-care regimens, including patients treated after enfortumab vedotin plus pembrolizumab. It

is among the first studies to prospectively select patients using a dual biomarker strategy, combining overexpression of the LP-184-activating

enzyme PTGR1 with tumor DNA-damage repair deficiency. LP-184 will be administered on Days 1 and 8 of each 21-day cycle, with objective

response rate by RECIST 1.1 as the primary endpoint.

Bladder

cancer is among the ten most common cancers worldwide, with approximately 550,000 new cases diagnosed annually, and there is no FDA-approved

therapy for nucleotide excision repair deficient tumors. Lantern is initially positioning LP-184 in a clinical trial where it will be

used primarily in the third-line setting. This represents approximately 130,000 eligible patients globally each year and a potential

market opportunity estimated by analysts at $3 billion or more by 2035.

LP-184

(zirdafulven): Expanded Patent Estate and Advancement in Triple-Negative Breast Cancer

July 2026, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, covering

methods of selecting and treating patients with ovarian, primary liver, kidney, or thyroid cancer with LP-184 based on measured elevated

expression of three genes — PTGR1, PTPN14, and ASPH — in a patient tumor sample. Lantern intends to continue expanding its

patent portfolio through additional filings covering further indications and biomarker-guided applications of LP-184.

Lantern

is preparing to initiate a Phase 1b/2 trial of LP-184 monotherapy in patients with relapsed or refractory advanced or metastatic triple-negative

breast cancer (TNBC) whose tumors carry DNA damage repair alterations, homologous recombination deficiency, or genomic loss of heterozygosity.

The study has been cleared by the FDA and is designed to enroll approximately 40 patients across two dose-level cohorts in Phase 1b to

confirm the recommended Phase 2 dose, followed by a Simon two-stage Phase 2a assessment of preliminary objective response rate. LP-184

completed a 63-patient Phase 1a trial (NCT05933265) achieving all primary endpoints and establishing a recommended Phase 2 dose of 0.39

mg/kg, and has received Fast Track and Orphan Drug designations from the FDA across multiple indications including TNBC.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

LP-284

and Starlight Therapeutics

LP-284

continues in an ongoing Phase 1 program in hematologic malignancies and adult soft tissue sarcomas, and holds FDA Orphan Drug Designations

for soft tissue sarcomas, mantle cell lymphoma, and high-grade B-cell lymphomas, with composition of matter patents providing protection

through 2039 in major medicine markets.

Starlight

Therapeutics holds FDA clearance of the Investigational New Drug application for its planned Phase 1 pediatric CNS cancer trial of STAR-001

(LP-184) in Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers. STAR-001 holds Rare Pediatric Disease Designation

and Orphan Drug Designation for ATRT, with additional designations for hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors.

Each Rare Pediatric Disease Designation independently qualifies for a potential FDA Priority Review Voucher upon potential approval and

satisfaction of other program conditions; such vouchers have historically been sold or transferred in the range of $100 million to $150

million or more, representing a potentially meaningful source of non-dilutive value independent of the commercial potential of the underlying

therapy. Starlight is also advancing plans for a Phase 1b trial of STAR-001 in adult patients with relapsed glioblastoma in combination

with spironolactone, where preclinical studies have demonstrated meaningful synergy relative to either agent alone. Lantern and Starlight

continue to explore partnership opportunities across both pediatric and adult CNS indications.

Financial

Results for the Second Quarter Ended June 30, 2026

Balance

Sheet: Cash, cash equivalents, and marketable securities were approximately $7.4 million as of June 30, 2026 (consisting of approximately

$6.7 million in cash and cash equivalents and approximately $0.7 million in marketable securities), compared to approximately $10.1 million

of cash, cash equivalents, and marketable securities as of December 31, 2025. Funding received during the second quarter consisted of

approximately $4.4 million in gross proceeds from a registered direct offering that closed on May 14, 2026. The Company intends to pursue

additional capital raises, collaborations and other opportunities to extend its operating runway.

Research

and Development Expenses: R&D expenses were approximately $1.8 million for the three months ended June 30, 2026, compared to

approximately $3.1 million for the three months ended June 30, 2025, a decrease of approximately $1.3 million or 42%. The decrease was

primarily attributable to reductions of approximately $1.0 million in research studies and materials expenses relating to the conduct

of our clinical trials and decreases of approximately $0.3 million in salaries and benefit expenses.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

General

and Administrative Expenses: G&A expenses were approximately $1.7 million for the three months ended June 30, 2026, compared

to approximately $1.6 million for the three months ended June 30, 2025, an increase of approximately $0.13 million or 8%. The increase

was primarily attributable to increases in business development and investor relations expenses of approximately $0.36 million and salaries

and benefit expense increases of approximately $0.14 million, offset in part by decreases in other professional fees of approximately

$0.35 million.

Operating

Loss: Loss from operations was approximately $3.5 million for the three months ended June 30, 2026, compared to a loss from operations

of approximately $4.7 million for the three months ended June 30, 2025, a decrease of approximately 25%.

Warrant

Expense: In connection with the May 2026 offering, the Company issued investor warrants to purchase up to 2,135,923 shares of common

stock at an exercise price of $2.27 per share, and placement agent warrants to purchase up to 106,796 shares of common stock at an exercise

price of $2.575 per share. These warrants are accounted for as liabilities due to a settlement feature that may be triggered in the event

of a fundamental transaction. During the three months ended June 30, 2026, the Company recorded an aggregate of approximately $3.6 million

of expense related to these warrants. The principal component was non-cash expense arising from an increase in the fair value of the

warrants, driven primarily by a substantial increase in the Company’s stock price between the May 14, 2026 warrant issuance date

and June 30, 2026. Other components related to warrant expense were loss on issuance of the warrants and warrant issuance costs.

Net

Loss: After including non-cash and other items relating to warrants, net loss was approximately $7.1 million (or $0.57 per share)

for the three months ended June 30, 2026, compared to a net loss of approximately $4.3 million (or $0.40 per share) for the three months

ended June 30, 2025. For the six months ended June 30, 2026, net loss was approximately $10.4 million (or $0.88 per share), compared

to a net loss of approximately $8.9 million (or $0.82 per share) for the six months ended June 30, 2025.

“Our reported net loss went up largely

because our stock price went up,” said Mr. Sharma. “That is warrant accounting, not the operating business. A key

number that shows how we actually run the company — loss from operations — fell approximately 25% in a quarter when we secured

European clearance for a new precision oncology trial and established a separate AI software company.”

Capitalization:

As of June 30, 2026, the Company had 12,759,146 shares of common stock outstanding. On May 14, 2026, the Company closed a registered

direct offering and concurrent private placement comprising 1,454,175 shares of common stock, pre-funded warrants to purchase up to 681,748

shares of common stock, investor warrants to purchase up to 2,135,923 shares of common stock at an exercise price of $2.27 per share,

and placement agent warrants to purchase up to 106,796 shares of common stock at an exercise price of $2.575 per share. There was no

activity under the Company’s ATM Sales Agreement during the three months ended June 30, 2026.

Additional

detail is available in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities

and Exchange Commission.

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

Conference

Call Information

Lantern

Pharma will host a conference call and webcast to discuss second quarter 2026 financial results and business updates on Friday, August

14, 2026 at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. To participate, please register at the Zoom webcast link: https://us06web.zoom.us/webinar/register/7017858906483/WN_muTjUTZiTNC4JYT9RXcKfQ#/registration

replay will be available following the call in the investor relations section of Lantern’s website at ir.lanternpharma.com.

About

Lantern Pharma

Lantern

Pharma (NASDAQ: LTRN) is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. Our

proprietary AI and machine learning platform, RADR®, leverages over 200+ billion oncology-focused data points and a library

of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development and generate oncology medicines

at dramatically reduced costs and accelerated timelines.

harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development

of our growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an

antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human

clinical trials in approximately two to three years and at approximately $2 to $3 million per program.

Our

lead development programs include a Phase 2 clinical program in never-smoker and non-smoker NSCLC, Phase 1b/2 trials in biomarker-defined

solid tumors, and an ongoing Phase 1 program in hematologic malignancies and adult soft tissue sarcomas. We have also established a wholly-owned

subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our therapies for CNS and brain cancers.

Lantern

established an AI Center of Excellence in Bengaluru, India in the first quarter of 2026 and has commercialized its multi-agentic AI capabilities

through the platform now operating as Open-Medicine AI (OMAI).

Our

AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.

●

Website: www.lanternpharma.com

●

HARMONIC™ Trial: www.harmonictrial.com

●

LinkedIn: https://www.linkedin.com/company/lanternpharma/

●

X: @lanternpharma

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating

to: future events or our future financial performance; the potential advantages of our RADR® platform and Open-Medicine

AI; the planned implementation of protocol amendments and the development pathway for LP-300 in patients harboring the EGFR exon 21 L858R

mutation; LP-300’s potential clinical activity and tolerability profile; the anticipated initiation, design, timing, conduct, and

potential of the planned Phase 1b/2 clinical trials of LP-184 (zirdafulven) in bladder cancer and in triple-negative breast cancer; the

anticipated benefits of a dual-biomarker patient-selection strategy; the establishment of Open Medicine AI as a separate entity and the

anticipated benefits of such separation, including its planned commercialization, funding, and potential future public emergence; our

plans to pursue additional funding and estimates regarding the sufficiency of capital resources; estimates regarding patient enrollment,

patient populations, potential markets and potential market sizes; and our plans to discover and develop drug candidates and to maximize

their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

Any

statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,”

“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”

“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”

“target,” “model,” “objective,” “aim,” “upcoming,” “should,”

“will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking

statements.

There

are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking

statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and

support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and emerging

or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or

successful, (iii) the risk that any clinical benefit observed to date relating to LP-300 may not be reproduced in the completed HARMONIC™

trial or in larger or confirmatory studies, (iv) the risk that clinical data referenced in this press release are exploratory and preliminary,

based on small patient cohorts, and may not be representative of outcomes in broader populations, (v) the risk that cross-trial comparisons

are provided for context only and should not be interpreted as direct evidence of comparative safety or efficacy, (vi) the risk that

our research and the research of our collaborators may not be successful, (vii) the risk that we may not be successful in licensing our

product candidates or in completing potential partnerships and collaborations, (viii) the risk that none of our product candidates has

received marketing approval from the FDA, the EMA or any other regulatory authority, and we may not be able to successfully initiate,

conduct, or conclude clinical testing for or obtain regulatory marketing approval for our product candidates, (ix) the risk that no drug

product based on our proprietary AI platforms has received FDA, EMA or other marketing approval or otherwise been incorporated into a

commercial product, (x) the risk that our AI platform commercialization efforts, including Open-Medicine AI, may not generate the anticipated

revenue or achieve the expected market adoption, (xi) the risk that the separation of Open Medicine AI may not deliver the anticipated

benefits on the contemplated terms or timeline or at all, (xii) the risk that investigator-initiated clinical trials, including the EMA-cleared

Phase 1b/2 trial of LP-184, may not initiate, enroll, or complete on the anticipated timeline or at all, and (xiii) those other factors

set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities

and Exchange Commission on March 30, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

You

may access our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter

ended June 30, 2026 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov.

Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that

any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors

not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the

date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform

the statement to actual results or changes in our expectations.

Lantern

Pharma Disclosure Channels to Disseminate Information

Lantern

Pharma’s investors and others should note that we announce material information to the public about our company through a variety

of means, including our website, press releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary

distribution of information to the public. We encourage our investors and others to review the information we make public in the locations

above as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Investor

Contact

Investor

Relations

ir@lanternpharma.com

+1-972-277-1136

###

Lantern Pharma (Nasdaq: LTRN) August 14, 2026

EX-99.2

Filename: ex99-2.htm · Sequence: 3

Exhibit 99.2

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (17644 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-2_001.jpg · Sequence: 5

Binary file (172580 bytes)

Download ex99-2_001.jpg

GRAPHIC

Filename: ex99-2_002.jpg · Sequence: 6

Binary file (738006 bytes)

Download ex99-2_002.jpg

GRAPHIC

Filename: ex99-2_003.jpg · Sequence: 7

Binary file (274285 bytes)

Download ex99-2_003.jpg

GRAPHIC

Filename: ex99-2_004.jpg · Sequence: 8

Binary file (252293 bytes)

Download ex99-2_004.jpg

GRAPHIC

Filename: ex99-2_005.jpg · Sequence: 9

Binary file (308905 bytes)

Download ex99-2_005.jpg

GRAPHIC

Filename: ex99-2_006.jpg · Sequence: 10

Binary file (243754 bytes)

Download ex99-2_006.jpg

GRAPHIC

Filename: ex99-2_007.jpg · Sequence: 11

Binary file (247129 bytes)

Download ex99-2_007.jpg

GRAPHIC

Filename: ex99-2_008.jpg · Sequence: 12

Binary file (365364 bytes)

Download ex99-2_008.jpg

GRAPHIC

Filename: ex99-2_009.jpg · Sequence: 13

Binary file (386476 bytes)

Download ex99-2_009.jpg

GRAPHIC

Filename: ex99-2_010.jpg · Sequence: 14

Binary file (350122 bytes)

Download ex99-2_010.jpg

GRAPHIC

Filename: ex99-2_011.jpg · Sequence: 15

Binary file (308691 bytes)

Download ex99-2_011.jpg

GRAPHIC

Filename: ex99-2_012.jpg · Sequence: 16

Binary file (339582 bytes)

Download ex99-2_012.jpg

GRAPHIC

Filename: ex99-2_013.jpg · Sequence: 17

Binary file (344253 bytes)

Download ex99-2_013.jpg

GRAPHIC

Filename: ex99-2_014.jpg · Sequence: 18

Binary file (329162 bytes)

Download ex99-2_014.jpg

GRAPHIC

Filename: ex99-2_015.jpg · Sequence: 19

Binary file (291148 bytes)

Download ex99-2_015.jpg

GRAPHIC

Filename: ex99-2_016.jpg · Sequence: 20

Binary file (272279 bytes)

Download ex99-2_016.jpg

GRAPHIC

Filename: ex99-2_017.jpg · Sequence: 21

Binary file (284978 bytes)

Download ex99-2_017.jpg

GRAPHIC

Filename: ex99-2_018.jpg · Sequence: 22

Binary file (265810 bytes)

Download ex99-2_018.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 27

v3.26.1

Cover

Aug. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 14, 2026

Entity File Number

001-39318

Entity Registrant Name

Lantern

Pharma Inc.

Entity Central Index Key

0001763950

Entity Tax Identification Number

46-3973463

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1920

McKinney Avenue

Entity Address, Address Line Two

7th Floor

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

(972)

Local Phone Number

277-1136

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value

Trading Symbol

LTRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration